{
    "clinical_study": {
        "@rank": "318",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04329195"
        },
        "id_info": {
            "org_study_id": "APHP200409",
            "nct_id": "NCT04329195"
        },
        "brief_title": "ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic",
        "acronym": "ACORES-2",
        "official_title": "ACE Inhibitors or ARBs Discontinuation for Clinical Outcome Risk Reduction in Patients Hospitalized for the Endemic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) Infection: the Randomized ACORES-2 Study",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Assistance Publique - H\u00f4pitaux de Paris",
                "agency_class": "Other"
            },
            "collaborator": {
                "agency": "Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re",
                "agency_class": "Other"
            }
        },
        "source": "Assistance Publique - H\u00f4pitaux de Paris",
        "oversight_info": {
            "has_dmc": "Yes",
            "is_fda_regulated_drug": "No",
            "is_fda_regulated_device": "No"
        },
        "brief_summary": {
            "textblock": "Since December 2019, a novel coronavirus called SARS-CoV-2 (severe acute respiratory syndrome\n      coronavirus 2) has caused an international outbreak of respiratory illness described as\n      COVID-19.\n\n      Individuals with a history of cardiovascular disease develop a more severe illness and have\n      higher rates of death.\n\n      Because of the potential interaction between RAS blockers and SARS-CoV-2 mechanism of\n      infection, there are ongoing scientific discussions on whether they should be stopped or\n      continued in patients with COVID-19.\n\n      It is crucial to determine whether RAS blockers should be discontinued or not in patients\n      with COVID-19."
        },
        "overall_status": "Recruiting",
        "start_date": {
            "@type": "Actual",
            "#text": "April 9, 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "May 9, 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "May 9, 2020"
        },
        "phase": "Phase 3",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "allocation": "Randomized",
            "intervention_model": "Parallel Assignment",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Time to clinical improvement from day 0 to day 28 (improvement of two points on a seven-category ordinal scale, or live discharge from the hospital, whichever comes first)",
            "time_frame": "from day 0 to day 28 or hospital discharge"
        },
        "secondary_outcome": [
            {
                "measure": "Primary safety endpoint: major adverse cardiac events defined as the composite of cardiovascular death, myocardial infarction, stroke or acute heart failure at day 28",
                "time_frame": "at day 28"
            },
            {
                "measure": "Clinical status as assessed with the seven-category ordinal scale on days 7, 14 and 28.",
                "time_frame": "at days 7, 14 and 28"
            },
            {
                "measure": "Number of days alive free of oxygen.",
                "time_frame": "from day 0 to day 28 or hospital discharge"
            },
            {
                "measure": "Number of days alive outside hospital until day28",
                "time_frame": "at day28"
            },
            {
                "measure": "Number of days alive free of intensive-care unit (ICU) admission or mechanical ventilation (invasive or non-invasive) until day28",
                "time_frame": "at day28"
            },
            {
                "measure": "Number of days alive free of mechanical ventilation (invasive or non-invasive) until day28",
                "time_frame": "at day28"
            },
            {
                "measure": "Number of days alive free of ICU admission until day28",
                "time_frame": "at day28"
            },
            {
                "measure": "Rate of all-cause mortality at day 28",
                "time_frame": "at day 28"
            },
            {
                "measure": "Rate of cardiovascular death at day 28",
                "time_frame": "at day 28"
            },
            {
                "measure": "Number of days alive free of acute kidney injury until hospital discharge",
                "time_frame": "at day 28 to hospital discharge"
            }
        ],
        "number_of_arms": "2",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "554"
        },
        "condition": "History of Cardiovascular Disease Treated With RAS Blockers and With SARS-CoV-2 Infection",
        "arm_group": [
            {
                "arm_group_label": "1: discontinuation of RAS blocker therapy",
                "arm_group_type": "Experimental",
                "description": "discontinuation of RAS blocker therapy"
            },
            {
                "arm_group_label": "2: continuation of RAS blocker therapy",
                "arm_group_type": "Active Comparator",
                "description": "continuation of RAS blocker therapy"
            }
        ],
        "intervention": [
            {
                "intervention_type": "Drug",
                "intervention_name": "1: discontinuation of RAS blocker therapy",
                "description": "discontinuation of RAS blocker therapy",
                "arm_group_label": "1: discontinuation of RAS blocker therapy"
            },
            {
                "intervention_type": "Drug",
                "intervention_name": "2: continuation of RAS blocker therapy",
                "description": "continuation of RAS blocker therapy",
                "arm_group_label": "2: continuation of RAS blocker therapy"
            }
        ],
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age \u2265 18 years old.\n\n          -  Chronically treated with RAS blockers (ACE inhibitors or ARBs on the last prescription\n             prior to admission with a treatment duration \u2265 1 month).\n\n          -  Diagnosis of COVID-19 confirmed by the presence of SARS-CoV-2 on any biological sample\n             with any detection method.\n\n          -  Patients hospitalized in a non-intensive care unit.\n\n          -  Pregnancy test at inclusion visit for women of childbearing potential.\n\n          -  Women of childbearing potential must agree to use adequate contraception according to\n             recommendations related to contraception and pregnancy testing in clinical trials, by\n             Clinical Trial Facilitation Group (CTFG).\n\n        Exclusion Criteria:\n\n          -  Shock requiring vasoactive agents.\n\n          -  Acute respiratory distress syndrome requiring invasive mechanical ventilation.\n\n          -  Circulatory assistance.\n\n          -  History of malignant hypertension according to the definition of the 2018 ESC/ESH\n             guidelines on hypertension.\n\n          -  Uncontrolled blood pressure despite the use of five antihypertensive drugs.\n\n          -  History of nephrotic syndrome.\n\n          -  History of hospitalization for hemorrhagic stroke in the past 3 months.\n\n          -  RAS blockers therapy previously stopped > 48h.\n\n          -  No affiliation to the French Health Care System \"S\u00e9curit\u00e9 Sociale\".\n\n          -  Inability to obtain informed consent."
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Gilles MONTALESCOT, MD, PhD",
            "role": "Principal Investigator",
            "affiliation": "Institut Cardiologie - Piti\u00e9 Salp\u00eatri\u00e8re(APHP) / ACTION Study Group / Univ. Paris 6 (UPMC) - INSERM UMRS 1166"
        },
        "overall_contact": {
            "last_name": "Gilles MONTALESCOT, MD, PhD",
            "phone": "+33 1 42 16 30 07",
            "email": "gilles.montalescot@aphp.fr"
        },
        "overall_contact_backup": {
            "last_name": "Mathieu KERNEIS, MD",
            "phone": "+33 1 42 16 30 74",
            "email": "mathieu.kerneis@aphp.fr"
        },
        "location": {
            "facility": {
                "name": "Cardiologie, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re",
                "address": {
                    "city": "Paris",
                    "zip": "75013",
                    "country": "France"
                }
            },
            "status": "Recruiting",
            "contact": {
                "last_name": "Gilles MONTALESCOT, MD, PhD",
                "phone": "+33 1 42 16 30 07",
                "email": "gilles.montalescot@aphp.fr"
            }
        },
        "location_countries": {
            "country": "France"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "March 28, 2020",
        "study_first_submitted_qc": "March 28, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 1, 2020"
        },
        "last_update_submitted": "April 12, 2020",
        "last_update_submitted_qc": "April 12, 2020",
        "last_update_posted": {
            "@type": "Estimate",
            "#text": "April 14, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "keyword": [
            "SARS-CoV-2",
            "Cardiovascular disease",
            "RAS blockers"
        ],
        "condition_browse": {
            "mesh_term": [
                "Infection",
                "Cardiovascular Diseases"
            ]
        },
        "intervention_browse": {
            "mesh_term": "Angiotensin-Converting Enzyme Inhibitors"
        }
    }
}